Eligible patients will have a histological diagnosis of colorectal cancer. The intent of the study is to enroll patients as quickly as possible once a decision has been made that a patient is a candidate for chemotherapy for stage 2-4 colorectal cancer. While many patients will be eligible for study participation at their initial consultation with medical oncology, it is also anticipated that some patients may need additional testing prior to eligibility. This would also include patients who have been followed in the medical oncology department that develop a new malignancy or have a recurrence. Patients must be enrolled to the study within 7 days of their initial consultation, or within 7 days of a physician visit, after any additional tests or biopsies have been completed, when the patient is felt to be a suitable candidate for chemotherapy. After obtaining informed consent from eligible patients, a commercially available pharmacogenomics panel, the OneOme RightMed® pharmacogenomic test, will be ordered. Patients will not be responsible for the cost of PGx testing. The study will not prescribe any specific chemotherapy regimens. All decisions regarding the clinical care of the patient will be made by the treating physician. Treatment will not be delayed to wait for PGx results per study protocol, however the treating physician may elect to do so. When PGx test results are available, results will be interpreted by the Oncology Lead Pharmacist at Essentia Health, and recommendations will be made to the treating physician regarding potential chemotherapy does adjustments. The treating physician will have the ultimate decision as to whether chemotherapy dose adjustments are done as a result of PGx testing. Patients will be seen by study staff prior to initiating chemotherapy, and after chemotherapy cycles 1-3 to assess for toxicity and to determine if any dose modifications were done by the treating physician.